FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
SurvivorNet on MSN2d
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
Zacks.com on MSN1d
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...
MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers
MEDSIR, a leading company dedicated to promoting independent clinical research in oncology internationally and part of ...
STAT2d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Medscape14h
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The Pharma Letter1d
Novartis’ Kisqali cleared for expanded indication by FDA
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...
Targeted Oncology6h
Elacestrant-Abemaciclib Combo Shows Promise for Breast Cancer
The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...
Targeted Oncology3d
Abemaciclib With ET Outperforms Chemotherapy in Advanced Breast Cancer
Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...
icr.ac.uk3y
POETIC-A: A trial of hormone therapy and abemaciclib for early breast cancer
POETIC-A is investigating whether adding the drug abemaciclib alongside hormone therapy can help prevent higher risk early breast cancer from returning. Abemaciclib works by blocking molecules which ...
Medpage Today on MSN2d
FDA Expands Approval of Ribociclib to Early Breast Cancer
The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...